Ī	FORM	PTO-1449	(Modified)	US DEPARTMENT OF		Docket No. 50623.379	Application No. 09/918,365			
ł	01	יש ואו	RMATION DISCLO	SURE CITATIO		Applicant	Michal	et al		
	NOV =	F 2001	in an Applic			Filing Date			Art Unit	
\ }	.104 [	5 2005 <sup>E</sup>		<u> </u>	NT DOC	July 30, 2001	1		1	762
1	ZA DE	MATHORN	<del></del>	U.S. PATE	NI DOCI		Class	ء ا	ubclass	Filing Date if
	Exam Initi		o. Document Number	Date of Patent		Name	Class		upcid55	Appropriate
	ī)	M) A1	2,072,303	3/2/37	He	errmann et al.	1+	_  _		
1	11	A2	2,386,454	10/9/45	F	Frosch et al.				
1		А3	3,773,737	11/20/73	G	oodman et al.				<del></del>
Ţ		A4	3,849,514	11/19/74	G	ray, Jr. et al.		$\perp$		
		<b>A</b> 5	4,226,243	10/7/80	S	halaby et al.				
		A6	4,329,383	. 5/11/82		Joh				
ľ		A7	4,343,931	8/10/82		Barrows				
	. A8		4,529,792	7/16/85		Barrows				
		A9	4,611,051	9/9/86	1	Hayes et al.				
		A10	4,656,242	4/7/87		Swan et al.				
		A11	4,733,665	3/29/88		Palmaz				
		A12	4,800,882	1/31/89		Gianturco		_		
		A13	4,882,168	11/21/89		Casey et al.				
		A14	4,886,062	12/12/89		Wiktor	$\bot \bot$			
j	·	A15	4,931,287	6/5/90		Bae et al.				
j		A16	4,941,870	7/17/90		Okada et al.		_		
		A17	4,977,901	12/18/90		Ofstead		$\perp$		
		A18	5,019,096	5/28/91	F	Fox, Jr. et al.		$\perp$	ļ	
		A19	5,100,992	3/31/92		Cohn et al.		$\perp$		
		A20	5,112,457	5/12/92		Marchant		$\bot$		
		A21	5,133,742	7/28/92		Pinchuk			1_	
		A22	5,163,952	11/17/92		Froix			$\perp$	
		A23	5,165,919	11/24/92	;	Sasaki et al.		$\Box$		
		A24	5,219,980	6/15/93		Swidler		$\prod$		
		A25	5,258,020	11/2/93		Froix				

mali	A26	5,272,012	12/21/93	Opolski					
1	A27	5,292,516	3/8/94	Viegas et al.					
	A28	5,298,260	3/29/94	Viegas et al.					
	A29	5,300,295	4/5/94	Viegas et al.					
	A30	5,306,501	4/26/94	Viegas et al.					
	A31	5,306,786	4/26/94	Moens et al.					
	A32	5,328,471	7/12/94	Slepian					
	A33	5,330,768	7/19/94	Park et al.					
	A34	5,380,299	1/10/95	Fearnot et al.		$\perp$			
	A35	5,417,981	5/23/95	Endo et al.			<u> </u>		
	A36	5,447,724	9/5/95	Helmus et al.					
	A37	5,455,040	10/3/95	Marchant					
	A38	5,462,990	10/31/95	Hubbell et al.					
	A39	5,464,650	11/7/95	Berg et al.					
	A40	5,485,496	1/16/96	Lee et al.	<u> </u>				
	A41	5,516,881	5/14/96	Lee et al.					·
	A42	5,569,463	10/29/96	Helmus et al.					
	A43	5,578,073	11/26/96	Haimovich et al.		<u>L</u>			
	A44	5,584,877	12/17/96	Miyake et al.					
	A45	5,605,696	2/25/97	Eury et al.					
	A46	5,607,467	3/4/97	Froix				$\perp$	
	A47	5,609,629	3/11/97	Fearnot et al.		<u> </u>		$\perp$	
	A48	5,610,241	3/11/97	Lee et al.					
	A49	5,616,338	4/1/97	Fox, Jr. et al.				$\perp$	
	A50	5,624,411	4/29/97	Tuch					
	A51	5,628,730	5/13/97	Shapland et al.					
	A52	5,644,020	7/1/97	Timmermann et al.					
	A53	5,649,977	7/22/97	Campbell					
	A54	5,658,995	8/19/97	Kohn et al.					
	A55	5,667,767	9/16/97	Greff et al.					
	A56	5,670,558	9/23/97	Onishi et al.					
	A57	5,674,242	10/7/97	Phan et al.			$\prod$		

Melk	A58	5,679,400	10/21/97	Tuch				
11	A59	5,700,286	12/23/97	Tartaglia et al.				
	A60	5,702,754	12/30/97	Zhong				
	A61	5,711,958	1/27/98	Cohn et al.		<u> </u>	<u> </u>	
	A62	5,716,981	2/10/98	Hunter et al.				
	A63	5,721,131	2/24/98	Rudolph et al.				
	A64	5,723,219	3/3/98	Kolluri et al.				
	A65	5,735,897	4/7/98	Buirge				
	A66	5,746,998	5/5/98	Torchilin et al.				
	A67	5,759,205	6/2/98	Valentini				
	A68	5,776,184	7/7/98	Tuch				
	A69	5,783,657	7/21/98	Pavlin et al.				,
	A70	5,788,979	8/4/98	Alt et al.				
	A71	5,800,392	9/1/98	Racchini				
	A72	5,820,917	10/13/98	Tuch			T	
	A73	5,824,048	10/20/98	Tuch				
	A74	5,824,049	10/20/98	Ragheb et al.				
	A75	5,830,178	11/3/98	Jones et al.				
	A76	5,837,008	11/17/98	Berg et al.				
	A77	5,837,313	11/17/98	Ding et al.				·
	A78	5,849,859	12/15/98	Acemoglu				
	A79	5,851,508	12/22/98	Greff et al.				
	A80	5,854,376	12/29/98	Higashi				
	A81	5,857,998	1/12/99	Barry			L.	
	A82	5,858,746	1/12/99	Hubbell et al.				
	A83	5,865,814	2/2/99	Tuch				
	A84	5,869,127	2/9/99	Zhong				,
	A85	5,873,904	2/23/99	Ragheb et al.				
	A86	5,876,433	3/2/99	Lunn			_	
	A87	5,877,224	3/2/99	Brocchini et al.				
	A88	5,879,713	3/9/99	Roth et al.				
	A89	5,902,875	5/11/99	Roby et al.	_			

_				·	<del>- 1</del>	1	1	
ab	MA90	5,905,168	5/18/99	Dos Santos et al.		<u> </u>		 
L	A91	5,910,564	6/8/99	Gruning et al.		<u> </u>		 
	A92	5,914,387	6/22/99	Roby et al.	<u> </u>			
	A93	5,919,893	7/6/99	Roby et al.				 
	A94	5,925,720	7/20/99	Kataoka et al.				
	A95	5,932,299	8/3/99	Katoot				
	A96	5,955,509	9/21/99	Webber et al.				 
	A97	5,958,385	9/28/99	Tondeur et al.				
	A98	5,962,138	10/5/99	Kolluri et al.				
	A99	5,971,954	10/26/99	Conway et al.				
	A100	5,980,928	11/9/99	.Terry				
	A101	5,980,972	11/9/99	Ding				
	A102	5,997,517	12/7/99	Whitbourne				
П	A103	6,010,530	1/4/00	Goicoechea				,
	A104	6,011,125	1/4/00	Lohmeijer et al.				
	A105	6,015,541	1/18/00	Greff et al.				
	A106	6,033,582	3/7/00	Lee et al.				·
	A107	6,034,204	3/7/00	Mohr et al.				
	A108	6,042,875	3/28/00	Ding et al.				
	A109	6,051,576	4/18/00	Ashton et al.				
	A110	6,051,648	4/18/00	Rhee et al.				
	A111	6,054,553	4/25/00	Groth et al.				
	A112	6,056,993	5/2/00	Leidner et al.				
	A113	6,060,451	5/9/00	DiMaio et al.				
	A114	6,060,518	5/9/00	Kabanov et al.				
	A115	6,080,488	6/27/00	Hostettler et al.				
	A116	6,096,070	8/1/00	Ragheb et al.				
	A117	6,099,562	8/8/00	Ding et al.				
	A118	6,110,188	8/29/00	Narciso, Jr.				
	A119	6,110,483	8/29/00	Whitbourne et al.				
	A120	6,113,629	9/5/00	Ken				
LV	A121	6,120,491	9/19/00	Kohn et al.				

	<del> </del>			<del></del>		$\overline{}$		1	1	T
b	22) A1	22	6,120,536	9/19/00	Ding et al.	-	$\bot$	ļ	1	
	A1	23	6,120,788	9/19/00	Barrows	$\perp$	$\perp$			
	A1	24	6,120,904	9/19/00	Hostettler et al.	<u> </u>	_	↓		
	A1	25	6,121,027	9/19/00	Clapper et al.		$\bot$	<u> </u>		
	A1	26	6,129,761	10/10/00	Hubbell		1_	$\perp$		
	A1	27	6,136,333	10/24/00	Cohn et al.	ļ	lacksquare			
	A1	28	6,143,354	11/7/00	Koulik et al.	_		$oxed{oxed}$		
	A1	29	6,153,252	11/28/00	Hossainy et al.					
	A1	30	6,159,978	12/12/00	Myers et al.		<u> </u>			
	A1	131	6,165,212	12/26/00	Dereume et al.	ļ				
	A1	132	6,172,167	1/9/01	Stapert et al.					
	A1	133	6,177,523	1/23/01	Reich et al.					
	A1	134	6,180,632	1/30/01	Myers et al.					
	A1	135	6,203,551	3/20/01	Wu					
	A1	136	6,211,249	4/3/01	Cohn et al.					
	A1	137	6,214,901	4/10/01	Chudzik et al.					
	A1	138	6,231,600	5/15/01	Zhong					
	A1	139	6,240,616	6/5/01	Yan					
	. A1	140	6,245,753	6/12/01	Byun et al.				_	
	A1	141	6,245,760	6/12/01	He et al.	$\prod$				
	A1	142	6,248,129	6/19/01	Froix	Ш		. <u> </u>		
	A1	143	6,251,136	6/26/01	Guruwaiya et al.					
	A1	144	6,254,632	7/3/01	Wu et al.					
	. A1	145	6,258,121	7/10/01	Yang et al.	$\prod$	<del>-</del>			
	A1	146	6,258,371	7/10/01	Koulik et al.	$\prod$				
	A1	147	6,262,034	7/17/01	Mathiowitz et al.				$\perp$	ļ
	A1	148	6,270,788	8/7/01	Koulik et al.					
	A1	149	6,277,449	8/21/01	Kolluri et al.			<u> </u>	$\perp$	
	A1	150	6,283,947	9/4/01	Mirzaee			<u> </u>	$\perp$	
	A1	151	6,283,949	9/4/01	Roorda	<u> </u>			$\perp$	
	V A1	152	6,284,305	9/4/01	Ding et al.					
Ц	AT.					<del>-</del> —	+	ــــــــــــــــــــــــــــــــــــــ	+	L

						├			
Den	) A153	6,287,628	9/11/01	Hossainy et al.				_	-
1/1	A154	6,299,604	10/9/01	Ragheb et al.	<u> </u>			<u> </u>	
	A155	6,306,176	10/23/01	Whitbourne	Ш				
	A156	6,331,313	12/18/01	Wong et al.					
	A157	6,335,029	1/1/02	Kamath et al.					
	A158	6,344,035	2/5/02	Chudzik et al.					
	A159	6,346,110	2/12/02	Wu					
	A160	6,358,556	3/19/02	Ding et al.					
	A161	6,379,381	4/30/02	Hossainy et al.					
	A162	6,387,379	5/14/02	Goldberg et al.					
	A163	6,395,326	5/28/02	Castro et al.					
	A164	6,419,692	7/16/02	Yang et al.					
	A165	6,451,373	9/17/02	Hossainy et al.		-	П		
	A166	6,482,834	11/19/02	Spada et al.					
	A167	6,494,862	12/17/02	Ray et al.					:
	A168	6,503,538	1/7/03	Chu et al.					
	A169	6,503,556	1/7/03	. Harish et al.					
	A170	6,503,954	1/7/03	Bhat et al.					,
	A171	6,506,437	1/14/03	Harish et al.					
	A172	6,524,347	2/25/03	Myers et al.					
	A173	6,527,801	3/4/03	Dutta					
	A174	6,527,863	3/4/03	Pacetti et al.					
•	A175	6,528,526	3/4/03	Myers et al.					
	A176	6,530,950	3/11/03	Alvarado et al.					
	A177	6,530,951	3/11/03	Bates et al.					
	A178	6,540,776	4/1/03	Sanders Millare et al.					
	A179	6,544,223	4/8/03	Kokish					
	A180	6,544,543	4/8/03	Mandrusov et al.					
	A181	6,544,582	4/8/03	Yoe					
	A182	6,555,157	4/29/03	Hossainy					
V	A183	6,558,733	5/6/03	Hossainy et al.				\	

MANA	<b>A</b> 184	6,565,659	5/20/03	Pacetti et al.	-		$\bigcap$	6/28/01
11	A185	6,572,644	6/3/03	Moein	1.			6/27/01
	A186	6,585,755	7/1/03	Jackson et al.				6/29/01
	A187	6,585,765	7/1/03	Hossainy et al.				6/29/00
	A188	6,585,926	7/1/03	Mirzaee				8/31/00
	A189	6,605,154	8/12/03	Villareal				5/31/01
	A190	6,623,448	9/23/03	Slater				3/30/01
	A191	6,625,486	9/23/03	Lundkvist et al.				4/11/01
	A192	6,645,135	11/11/03	Bhat				3/30/01
	A193	6,645,195	11/11/03	Bhat et al.				1/5/01
	A194	6,656,216	12/2/03	Hossainy et al.				6/29/01
	A195	6,656,506	12/2/03	Wu et al.				5/09/01
	A196	6,660,034	12/9/03	Mandrusov et al.				4/30/01
	A197	6,663,662	12/16/03	Pacetti et al.				12/28/00
	A198	6,666,880	12/23/03	Chiu et al.				6/19/01
	A199	6,673,154	1/6/04	Pacetti et al.				6/28/01
	A200	6,673,385	1/6/04	Ding et al.				6/28/01
	A201	6,689,099	2/10/04	Mirzaee				2/27/01
	A202	6,695,920	2/24/04	Pacetti et al.				6/27/01
	A203	6,706,013	3/16/04	Bhat et al.		-		6/29/01
	A204	6,712,845	3/30/04	Hossainy	П			4/24/01
	A205	6,713,119	3/30/04	Hossainy et al.				12/23/99
	A206	6,716,444	4/6/04	Castro et al.				9/28/00
	A207	6,740,040	5/25/04	Mandrusov et al.				1/30/01
	A208	6,743,462	6/1/04	Pacetti	·			5/31/01
	A209	6,749,626	6/15/04	. Bhat et al.				11/17/00
	A210	6,758,859	7/6/04	Dang et al.				10/30/00
	A211	6,759,054	7/6/04	Chen et al.				12/28/00

12m	A212	6,764,505	7/20/04	Hossainy et al.			4/12/01
IXIVO	A213	6,887,485	5/3/05	Fitzhugh et al.		1	5/25/01
1	A214	6,899,731	5/31/05	Li et al.	1.1		1/2/01
	/ LE 14			ION PUBLICATION DOCL	JMENTS	И	
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date I
M	A915	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
	A216	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A217	2001/0007083	7/5/01 .	Roorda			12/21/00
	A218	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A219	2002/0120326	8/29/02	Michal			12/22/00
	A220	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A221	2001/0018469	8/30/01	Chen et al.			12/28/00
	A222	2002/0123801	9/5/02	Pacetti et al.			12/28/0
	A223	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A224	2003/0032767	2/13/03	Tada et al.			2/5/01
	A225	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A226	2002/0142039	10/3/02	Claude			3/30/01
	A227	2002/0155212	10/24/02	Hossainy			4/24/01
	A228	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A229	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A230	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A231	2002/0007214	1/17/02	Falotico			5/7/01
	A232	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A233	2002/0016625	2/7/02	Falotico et al.			5/7/01
	A234	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A235	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A236	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A237	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A238	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A239	2002/0071822	6/13/02	Uhrich			7/27/01
V			FOREIGN PA	ATENT DOCUMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation Yes N

An	₩ B1	2001-190687	7/17/01	Japan (English Abstract)			
7	B2	DE 42 24 401	1/27/94	Germany			
	В3	EP 0 301 856	2/1/89	EPO			
	B4	EP 0 396 429	11/7/90	EPO			
	B5	EP 0 514 406	11/25/92	EPO			
	B6	EP 0 604 022	6/29/94	EPO			
	В7	EP 0 623 354	11/9/94	EPO		_	
	В8	EP 0 665 023	8/2/95	EPO		 	
	В9	EP 0 701 802	3/20/96	EPO			
	B10	EP 0 716 836	6/19/96	EPO			
	B11	EP 0 809 999	12/3/97	EPO			
	B12	EP 0 832 655	4/1/98	EPO			
	B13	EP 0 850 651	7/1/98	EPO	,		
	B14	EP 0 879 595	11/25/98	EPO			
	B15	EP 0 910 584	4/28/99	EPO			
	B16	EP 0 923 953	6/23/99	EPO			
	B17	EP 0 953 320	11/3/99	EPO			
	B18	EP 0 970 711	1/12/00	EPO			
	B19	EP 0 982 041	3/1/00	EPO			
	B20	EP 1 023 879	8/2/00	EPO			
	B21	EP 1 192 957	4/3/02	EPO			
	B22	EP 1 273 314	1/8/03	EPO			
	B23	SU 790725	2/9/83	SU (English Abstract)			
,	B24	SU 811750	9/23/83	SU (English Abstract)			
7 96	B25	SU 872531	10/15/81	SU (English Abstract)		) I I	A
	B26	SU 876663	10/30/81	SU (English Abstract)			
	B27	SU 905228	2/15/82	SU (English Abstract)			
	B28	SU 1016314	5/7/83	` SU (English Abstract)			
	B29	SU 1293518	2/28/87	SU (English Abstract)			
	B30	WO 91/12846	9/5/91	PCT			
	B31	WO 94/09760	5/11/94	PCT			
1	/ B32	WO 95/10989	4/27/95	PCT			

Ann	B33	WO 95/24929	9/21/95	PCT		
	B34	WO 96/40174	12/19/96	PCT		
	B35	WO 97/10011	3/20/97	PCT		
	B36	WO 97/45105	12/4/97	PCT		
	B37	WO 97/46590	12/11/97	PCT		
	B38	WO 98/08463	3/5/98	PCT		
	B39	WO 98/17331	4/30/98	PCT		
	B40	WO 98/32398	7/30/98	PCT		
	B41	WO 98/36784	8/27/98	PCT		
	B42	WO 99/01118	1/14/99	PCT		
	B43	WO 99/38546	8/5/99	PCT		
	B44	WO 99/63981	12/16/99	PCT		
	B45	WO 00/02599	1/20/00	PCT		
	B46	WO 00/12147	3/9/00	PCT		
	B47	WO 00/18446	4/6/00	PCT		
	B48	WO 00/64506	11/2/00	PCT		
	B49	WO 01/01890	1/11/01	PCT		
	B50	WO 01/15751	3/8/01	PCT		
	B51	WO 01/17577	3/15/01	PCT		
	B52	WO 01/45763	6/28/01	PCT		
	B53	WO 01/49338	7/12/01	PCT		
	B54	WO 01/51027	7/19/01	PCT		
	B55	WO 01/74414	10/11/01	PCT		
	B56	WO 02/003890	1/17/02	PCT		
	B57	WO 02/026162	4/4/02	PCT		
	B58	WO 02/034311	5/2/02	PCT		
	B59	WO 02/056790	7/25/02	PCT		
	B60	WO 02/058753	8/1/02	PCT	<u>.                                    </u>	
	B61	WO 02/102283	12/27/02	PCT		
	B62	WO 03/000308	1/3/03	PCT		
	B63	WO 03/022323	3/20/03	PCT		
V	B64	WO 03/028780	4/10/03	PCT		

							<del></del>			
de	√B65	WO 03/037223	5/8/03	PCT						
1	B66	WO 03/039612	5/15/03	PCT						
	B67	WO 03/080147	10/2/03	PCT						
	B68	WO 03/082368	10/9/03	PCT						
	B69	WO 04/000383	12/31/03	, PCT						
1/	B70	WO 04/009145	1/29/04	РСТ						
	<del> </del>	OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertinent F	ages, etc.)					
1/2	C1			he Dream Stent, Clinica 710:15 (. t?req=1061848202959, printed 8						
	C2			complications by 30%, Clinica 73 tt?req=1061847871753, printed 8			),			
C3 Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						ated St	ent			
C4 Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061848017752">http://www.dialogweb.com/cgi/document?req=1061848017752</a> , printed 8/25/03 (2 pages).  C5 Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive Journal of Controlled Release 32:87-96 (1994).										
						nsive ma	ateria			
	C6	Barath et al., Low Do Injury, JACC 13(2): 2		rents Prevents Smooth Muscle Ce bb. 1989).	ell Proliferati	ion After	Endoth	elial		
	C7	Barbucci et al., Coatii Mater. Res. 25:1259-		available materials with a new h	əparinizable	materia	<i>I</i> , J. Bio	med		
	C8	Chung et al., Inner co Journal of Controlled		n for drug delivery control of them 3 (2000).	no-responsi	responsive polymeric micell				
	C9			he Arterial Wall Via Polyurethane eterization and Cardiovascular Di						
	C10	Dichek et al., Seeding 80(5):1347-1353 (No		Stents with Genetically Engineere	d Endothelia	al Cells,	Circ.			
	C11	Eigler et al., Local An	erial Wall Drug De	elivery from a Polymer Coated Re , JACC, 4A (701-1), Abstract (Fel		∍tallic Ste	ent: Kind	etics		
Ŀ	C12	Helmus, Overview of	Biomedical Mater	ials, MRS Bulletin, pp. 33-38 (Sep	t. 1991).					
	C13	Herdeg et al., <i>Antipro</i> 3:197-199 (1998).	liferative Stent Co	atings: Taxol and Related Compo	unds, Semi	n. Interve	ent. Car	diol.		
	C14		adable Polymers L	Derived from Aminoacids, Macron	nol. Symp. 1	144, 7-32	(1999)	)		
C15 Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).						nicellar				
	C16			s as vehicles for drug delivery, Jo		ntrolled f	Release	)		
	C17	amide)s Based on Bis	s(α-amino acid)α,υ	analogous Polymers. Synthesis a o-Alkylene Diesters, and Aliphatic mistry, 37(4), 391-407 (1999).						
1	C18 Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).									

Mn	C19	Liu et al., Drug release characteristics of unimolecular polymeric micelles, Journal of Controlled Release 68:167-174 (2000).
0	C20	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
	C21	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
	C22	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
	C23	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
	C24	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
	C25	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).
	C26	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
	C27	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
		Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
	C29	Saotome, et al., Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid, Chemistry Letters, pp. 21-24, (1991).
		Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).
,	C31	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
	C32	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
	C33	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid turnor, Journal of Controlled Release 50:79-92 (1998).
EXAMINER		K Muchen DATE CONSIDERED 1/3)/06
		erences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.